Utility of Ga-68 DOTA PET-CT in Neuroendocrine Tumours
Neuroendocrine tumours are a diverse group of relatively rare cancers, with a reported incidence of 9 cases per 100,000 people in 2015.
Recently there have been major advances in their diagnosis, staging and treatment. The possibility of multiple options to investigate and treat a diverse range of rare tumours represents a challenge for all members of the MDT, not least the radiologist.
The course aims to provide an overview of the use of Ga-68 DOTA PET-CT in the diagnosis and treatment of patients with neuroendocrine tumours.
It is expected that candidates have prior knowledge of FDG PET-CT imaging before undertaking the tutorial.
Suitable for radiologists and nuclear medicine physicians who intend to train to report on the utility of Ga-68 DOTA PET-CT neuroendocrine tumour imaging and molecular radiotherapy, or who otherwise encounter these studies in their practice and wish to increase their confidence, for example in the role of a presenting radiologist at an MDT.
Learning Outcomes
- Explain how 68Ga and 18F is created.
- Describe how 68Ga-DOTATOC is absorbed into the body.
- Discuss the differences between 68Ga and 18FDG.
Please note: To mark this course as complete on your Learning Dashboard and access your certificate of completion, you must finish all learning modules and submit the course evaluation.
-
Jose Calero
José Calero, BPharm, MSc, GPhC, is a Consultant Radiopharmacist and Head of Radiopharmacy at The Christie NHS Foundation Trust. He earned his Pharmacy degree (2005) from The University of Seville and specialized in radiopharmacy through a three-year training program in Spain. He also holds an MSc in Medical Physics (2010) from the University of Granada. Since 2012, he has led one of the UK’s largest radiopharmacies, manufacturing 11,000+ vials annually. He has been a UK Radiopharmacy Group member since 2014.
